Emergent Biosolutions
EBS
EBS
198 hedge funds and large institutions have $1.5B invested in Emergent Biosolutions in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 80 increasing their positions, 54 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
9% more funds holding
Funds holding: 181 → 198 (+17)
3.05% more ownership
Funds ownership: 86.95% → 90% (+3.1%)
Holders
198
Holding in Top 10
–
Calls
$3.1M
Puts
$2.08M
Top Buyers
| 1 | +$13.4M | |
| 2 | +$6.65M | |
| 3 | +$6.23M | |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.94M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.45M |
Top Sellers
| 1 | -$11.2M | |
| 2 | -$8.62M | |
| 3 | -$5.2M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.89M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$3.48M |